J Biomed Mater Res A:鉴定COPINE-7蛋白细胞穿透成骨肽及其增强骨形成的传递系统

2019-06-13 不详 网络

肽和蛋白质被认为是高选择性和治疗活性的生物材料,并且在临床应用中相对安全。最近发现钙磷脂结合蛋白,copine VII(CPNE7)通过内化到细胞中诱导硬组织再生,包括骨和牙本质。然而,全长CPNE7的临床应用由于其大尺寸和短半衰期而受到限制。在此,作为CPNE7的替代,从CPNE7(CPNE7衍生的肽,CDP1-6)设计了六种生物活性合成肽并研究了它们的成骨潜力。在CDP中,CDP4在牙髓干细胞

肽和蛋白质被认为是高选择性和治疗活性的生物材料,并且在临床应用中相对安全。最近发现钙磷脂结合蛋白,copine VII(CPNE7)通过内化到细胞中诱导硬组织再生,包括骨和牙本质。然而,全长CPNE7的临床应用由于其大尺寸和短半衰期而受到限制。在此,作为CPNE7的替代,从CPNE7(CPNE7衍生的肽,CDP1-6)设计了六种生物活性合成肽并研究了它们的成骨潜力。

在CDP中,CDP4在牙髓干细胞(DPSC)中具有最高水平的细胞穿透活性以及成骨效率。 CDP4增加了成骨相关基因和蛋白质的表达,这与BMP-2的表达相当。CDP4的细胞穿透能力可以协同诱导DPSC的成骨潜力。此外,CDP4与可注射胶原凝胶的混合物的植入增加了骨形成,并且在小鼠颅骨缺损模型中恢复,与全长CPNE7甚至BMP-2相当。

总之,这些结果表明我们的合成肽CDP4可以与生物材料组合应用,以在骨组织工程领域中提供高成骨功效。

原始出处:

Lee DW, Park KS, et al., Identification of cell penetrating osteogenic peptide from COPINE-7 protein and its delivery system for enhanced bone formation. J Biomed Mater Res A. 2019 Jun 7. doi: 10.1002/jbm.a.36746.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1918737, encodeId=605e1918e37ef, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue May 19 11:20:00 CST 2020, time=2020-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352163, encodeId=5294135216356, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jun 15 06:20:00 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609819, encodeId=4447160981978, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jun 15 06:20:00 CST 2019, time=2019-06-15, status=1, ipAttribution=)]
    2020-05-19 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1918737, encodeId=605e1918e37ef, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue May 19 11:20:00 CST 2020, time=2020-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352163, encodeId=5294135216356, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jun 15 06:20:00 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609819, encodeId=4447160981978, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jun 15 06:20:00 CST 2019, time=2019-06-15, status=1, ipAttribution=)]
    2019-06-15 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=1918737, encodeId=605e1918e37ef, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue May 19 11:20:00 CST 2020, time=2020-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352163, encodeId=5294135216356, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jun 15 06:20:00 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609819, encodeId=4447160981978, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jun 15 06:20:00 CST 2019, time=2019-06-15, status=1, ipAttribution=)]